Oncopharmpod

Lenvatinib vs. Sorafenib (HCC)

Informações:

Synopsis

Reviewing the REFLECT (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30207-1/fulltext) study and its take-home points on selecting an agent for advanced HCC.